Entries by

LEQEMBI® Wins Best New Drug And Clinical Advance Of The Year at The Scrip Awards 2023

TOKYO and CAMBRIDGE, Mass., November 20, 2023 – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that Alzheimer’s disease (AD) treatment LEQEMBI® (lecanemab-irmb) was awarded both the Best New Drug and Clinical Advance of the Year for the Phase III Clarity AD study at the Scrip Awards 2023, held by Citeline (Headquarters: New York).

2023/11/20 by

EISAI NAMED AS “GREATEST IR IMPROVEMENT PREMIUM COMPANY” AND “BEST CONTINUAL IR EFFORTS PREMIUM COMPANY” AT THE JAPAN INVESTOR RELATIONS ASSOCIATION 30TH ANNIVERSARY COMMEMORATIVE AWARDS

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has been named by the Japan Investor Relations Association (Chairman: Naoki Izumiya, “JIRA”) as one of the “Greatest IR Improvement Premium Company” and “Best Continual IR Efforts Premium Company” at the JIRA 30th Anniversary Commemorative Awards.

2023/11/16 by

“LEQEMBI® Intravenous Infusion” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan

TOKYO and CAMBRIDGE, Mass., September 25, 2023 – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that humanized anti- soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI® Intravenous Infusion” (200 mg, 500mg, lecanemab) has been approved in Japan as a treatment for slowing progression of mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s disease (AD).

2023/9/25 by

Results of Today’s Discussion on Lecanemab at Japan’s First Committee on New Drugs of the Pharmaceutical Affairs and Food Sanitation Council

Eisai Co., Ltd. (Headquarters: Tokyo) and Biogen Inc. (Headquarters: Cambridge, Massachusetts) announced the following joint statement regarding today’s recommendation by Japan’s First Committee on New Drugs of the Pharmaceutical Affairs and Food Sanitation Council of the Ministry of Health, Labour and Welfare that the manufacturing and marketing authorization application for lecanemab (product names: Leqembi 200 mg for intravenous infusion and Leqembi 500 mg for intravenous infusion) should be approved.

2023/8/21 by

EISAI TO PRESENT THE LATEST ALZHEIMER’S DISEASE PIPELINE AND RESEARCH, INCLUDING LECANEMAB AND ANTI-MTBR TAU ANTIBODY E2814, AT THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2023

Eisai Co. Ltd (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the company will present the latest findings on its Alzheimer’s disease (AD) pipeline and research, including Eisai’s anti-amyloid beta (Aβ) protofibril* antibody for the treatment of Alzheimer’s disease (AD), lecanemab (generic name, U.S. brand name: LEQEMBI®), and the company’s investigational anti-MTBR** tau antibody, E2814, at the Alzheimer’s Association International Conference (AAIC). The conference will be held in Amsterdam, the Netherlands and virtually from July 16 to 20, 2023. Eisai will present data and research in eight oral and 19 poster presentations at the meeting. Two of the AAIC oral presentations will be presented as posters at the Alzheimer’s Disease Imaging Consortium (AIC), which will be held at the same venue as AAIC on July 15.

2023/7/12 by

Copyright(c) 2011 Eisai China lnc.All Rights Reserved.
沪ICP备11005394号-1
沪公网安备31010602001439号

Customer Service Hotline

021-62881220

LINKS

• Record information of Representative
• 已上市替普瑞酮胶囊铬限量检验报告公示说明

More Information

• Privacy Policy
• Legal Notices
• Accessibility